Extraction and clearance kinetics of [1-'1Clacetate were examined in 65 experiments in 30
Several studies have examined the usefulness of [1- .C]acetate as a tracer of myocardial oxidative metabolism. Early work with positron emission tomography (PET) and [1-`C] acetate in open-chest dogs' and humans2 revealed monoexponential clearance of`lC activity from myocardium after intravenous injection of cardiac workload was associated with an increase in the`1C clearance rate constant, suggesting a correlation between myocardial oxygen consumption and`lC washout after [1-1'C]acetate injection. In addition, tracer clearance was delayed in myocardial regions with electrocardiographic evidence of acute ischemia in patients with coronary artery disease.
A recent study in our laboratory in isolated, perfused rat hearts demonstrated biexponential`4C clearance after [1-1'4C]acetate administration. 3 There was a close correlation between the slope of the rapid clearance phase and the tricarboxylic acid (TCA) cycle flux under varying work load conditions. In contrast to results with labeled palmitate, changes in substrate supply did not alter the tissue kinetics of [1-1'4C]acetate except after administration of acetate in nontracer amounts, equivalent to nonphysiologically high acetate serum levels. Similar results were published by Brown et al,4 who found biexponential 1`C clearance from normoxic, perfused, isolated rabbit hearts and monoexponential clearance in ischemia after administration of [ The present study was designed to assess [l-lacetate clearance kinetics in the more controlled setting of the open-chest dog under various blood flow and metabolic conditions: at control, during ischemia, after reperfusion, and in dipyridamoleinduced hyperemia. Intracoronary tracer injection was performed to obtain a primary tissue clearance curve and to minimize tracer recirculation. With a previously described method, 8 10 the single-pass extraction fraction of [1-1'C]acetate was calculated from the recorded tissue-time activity curves. Invasive measurements of regional myocardial blood flow, oxygen, and substrate consumption were obtained to examine whether any of these parameters affect extraction fraction or [1-1"C]acetate tissue clearance kinetics. Data were acquired with a gamma probe to obtain better counting statistics at faster highresolution sampling rates than possible with PET.
Furthermore, total`4C activity and 14CO2 were measured in the coronary sinus or coronary vein effluent after intracoronary coinjection of [1-_4C] acetate to determine the extent to which washout of`C activity after [1-'1C] acetate injection reflects CO2 production and TCA cycle activity. The aim of this study was thus to define more accurately the tissue kinetics of [1-"C]acetate as a tracer of myocardial oxidative metabolism and to delineate factors that might alter the tissue kinetics of this tracer.
Methods

Surgical Preparation
Thirty mongrel dogs, weighing 18.5-27 kg (mean weight, 21.3 +2.2 kg), were anesthetized with thiamy-lal 20 mg/kg initially and sodium pentobarbital as needed to maintain anesthesia, intubated, and ventilated with room air by a respirator (Harvard Apparatus, Millis, Massachusetts). Catheters were advanced into the aorta through one femoral and one carotid artery for blood pressure monitoring and withdrawal of arterial blood. After a left thoracotomy, the pericardium was incised widely and sutured to the chest wall, suspending the heart in a pericardial cradle. A polyvinyl catheter was placed in the left auricle for microsphere injection and withdrawal of blood samples. Another polyvinyl catheter was placed in the coronary sinus for venous blood sampling. A 25-gauge needle with a rectangular bend at the tip, connected to fine plastic tubing, was inserted into the proximal part of the left anterior descending coronary artery (LAD) for intracoronary tracer injections. In ischemia, hyperemia, and postischemia experiments, a screw-type coronary occluder and an electromagnetic flow probe (Pulsed-Logic Electromagnetic Blood Flowmeter, Biotronex Laboratory, Kensington, Maryland) were placed around the LAD proximal to the intracoronary needle. A cannula was inserted into the cardiac vein draining the myocardium supplied by the LAD to obtain venous blood samples from the ischemic, postischemic, or hyperemic anterior wall. The anterior interventricular vein was chosen for regional blood sampling because it drains blood only from the LAD territory. Venous effluent is therefore practically uncontaminated by venous blood draining from left circumflex coronary artery or right coronary artery.11-13
Study Protocol
Sixty-five experiments were performed in the 30 dogs. Immediately before each tracer injection, blood samples were obtained from the left atrium and the coronary sinus or great coronary vein for blood gas, hematocrit, serum glucose, free fatty acid, and lactate measurements. Continuous heart rate and blood pressure monitoring with an eight-channel strip chart recorder (Gould, Inc, Cleveland, Ohio) was maintained throughout all experiments. In studies including hyperemia or ischemia, coronary blood flow was measured continuously with a flow probe to determine stability of flow changes throughout the experiments. Blood pressure, heart rate, and coronary blood flow were calculated every 5-7 minutes during the experiments. Mean values during the studies were 4.0+3.3% for blood pressure, 3.4±2.8% for heart rate, and 8.8±7.3% for coronary blood flow.
Thus, hemodynamic stability was maintained throughout all experiments. Microspheres were injected into the left atrium with simultaneous reference sampling of arterial blood to determine myocardial blood flow.14 The increase in background activity due to microspheres was monitored before each [1-11C] acetate experiment and subtracted from overall activity during the runs to permit accurate "C decay correction.
Subsequently, a bolus of 80-150 gCi [1-11C]acetate, diluted with saline 0.9% to a volume of 0.2-0.3 ml, was loaded into the tubing attached to the LAD needle and then flushed rapidly into the LAD with 1 ml saline. Myocardial`1C activity was recorded with a leadshielded and collimated Nal (T1) scintillation detector. The diameter of the detector was 5.5 cm, and the opening of the lead shielding, which was 8 cm below the detector, was 7.5 cm in diameter and led to a field of view at the myocardium of approximately 11 cm in diameter. The field of detection encompassed the myocardium supplied by the LAD, but it excluded the site of tracer administration. Activity counting was performed in 100-msec intervals for a period of 40 minutes, the data being transferred to a digital computer (Microvax, Digital Equipment Corp, Maynard, Massachusetts). Subsequently, one or two injections were repeated at intervals of at least 1 hour, allowing background activity to return to levels less than 5% of peak activity because of the short physical (20.4 minutes) and biological half-life of [1-11C]acetate.
Study Subgroups
Group 1. Eleven experiments were performed in nine anesthetized dogs without any kind of intervention. To extend the range of cardiac work and thus myocardial oxygen consumption, atrial pacing with frequencies between 160 and 220 beats/min or infusion of methoxamine hydrochloride 20 mg i.v. (Vasoxyl, Burroughs Wellcome, Research Triangle Park, North Carolina) were performed in four studies in four dogs. In another 11 experiments in four dogs, dobutamine (Dobutrex, Eli Lilly Industries, Indianapolis, Indiana) was infused intravenously at a rate of 5-10 ,ug/kg/min. Cardiac workload was reduced in three experiments in three dogs by intramuscular administration of morphine (30-60 mg) and intravenous propranolol (2-3 mg). These group 1 studies with no interventions other than changes in cardiac workload, which were maintained throughout the study period, will subsequently be referred to as the control group. Group 2. To evaluate selectively the effect of myocardial blood flow on acetate kinetics, intravenous dipyridamole (0.15 mg/min/kg; persantine, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut) was infused continuously throughout the experiments in 13 studies in six dogs, thus uncoupling myocardial blood flow and MVo2. The signal from the electromagnetic flow probe indicated steady-state flow conditions throughout all experiments with a mean of 9.0±7.1% for the entire study period. Group 3. The validity of [1-11C] acetate as a tracer of oxidative metabolism in myocardial ischemia has not yet been explored in situ in large animals. Therefore, [1-1'C]acetate kinetics were evaluated in 13 studies in six dogs after partial occlusion of the proximal LAD. Reductions in myocardial blood flow in the affected myocardial regions were verified by microsphere measurements. Flow in the ischemic segments was reduced to 33.1 ± 19.1% compared with the surrounding normally perfused myocardium.
When several studies were performed in one dog, the partial coronary occlusion was maintained during all experiments. Group 4. To determine the usefulness of [1-J1C] acetate to measure MVo2 in the setting of reperfusion, the tissue kinetics of [1-1'C]acetate were evaluated in eight studies in three dogs after release of LAD occlusion. Serial acetate injections were performed after one 30-minute occlusion period. Heart rate and systemic blood pressure remained stable throughout each experiment.
To assess the impact of sudden changes in cardiac workload on acetate clearance, cardiac pacing was initiated after 7 minutes at a heart rate of 200 beats/min in one experiment. In another experiment, [1-11C] acetate was injected during pacing, and cardiac workload decreased suddenly by cessation of pacing and return to sinus rhythm after 6 minutes. Before the dogs were killed, lissamine green was injected into the LAD in all experiments to delineate the myocardium supplied by the LAD. The dogs were killed by injection of pentobarbital and highly concentrated potassium chloride solution, and the hearts were excised rapidly. Last, tissue samples were obtained for microsphere activity measurements, with a well counter (Auto gamma well counter Micrad, Inc, Harriman, Tennessee) to determine myocardial blood flow values after weighing the samples. 
Data Processing
The recorded time activity data were transferred to a VAX 780 computer (Digital Equipment Corp) and corrected for physical decay of '1C. Tissue-time activity curves were subsequently generated in different time resolution modes ( Figure 1A and B) and fitted with a multiexponential curve-fitting routine according to the following equation:
In all experiments, a delay in 1`C washout preceded the biexponential clearance of`1C activity and resulted in a characteristic hump on the clearance phase, subsequently called "hump phase" ( Figure 1A ). This hump phase was not accounted for by the biexponential curve fitting and needed separate fitting.
Fitting was initiated at the end of the delay in 1`C washout (hump phase, Figure 1A ), myocardial clearance thereafter following a biexponential pattern in all experiments. Parameters k1 and k2 in Equation 1
define the rate constants (k=ln2/T1/2) for the two myocardial clearance components. Separate rate constants (kinj3 for the initial delay in 1`C clearance were obtained by fitting only the first 160 seconds of the myocardial tissue-time activity curve with a higher (1 point/sec) time resolution display ( Figure  1B ). First-pass extraction fraction of [1-1"C]acetate, that is, the fraction of activity retained in the myocardium after one passage of the tracer through the coronary vascular bed, was calculated by extrapolating the initial part (hump phase) of the myocardial clearance curve to the time of maximum activity. The activity value hereby obtained (B) is given as percentage of the maximum activity (A), which is proportional to the entire amount of the injected activity:
The relative amount of`1C activity entering each of the two major clearance phases was determined by extrapolating the monoexponential curve fit of each component back to the time of maximum activity ( Figure 1A ).
Assessment of Myocardial CO2 Production With [1-_4CjAcetate
In 24 of the experiments (groups 1-4), 20 ,uCi [1-_4C]acetate was coinjected into the LAD with [l-"C] acetate. Two-milliliter blood samples were taken simultaneously from the coronary sinus, or a coronary vein draining the myocardium in the region of intervention supplied by the LAD, and an arterial line. Sampling was initiated 1-2 minutes after injection, depending on ease of blood withdrawal, and continued at 1-minute intervals up to 10 minutes after [1-'4C]acetate injection and at 3-minute intervals for the next 15 minutes. Total "4C activity and 14C02 activity in each of the 2-ml blood samples were measured by the method described by Buffington et al. 15 The samples were transferred to a flask containing a small plastic vial with phenylethylamine (0.3 ml) and acidified with 1 ml of 6N HCl. The 14C02 released by this procedure was trapped in phenylethylamine and quantified by liquid scintillation counting. The remaining 14C activity in the flask, representing non-CO2`4C, was also determined by liquid scintillation counting of an aliquot. Arteriovenous differences for non-CO2 14C and 14C02 were calculated, and the contribution of '4C02 to total 14C activity released from the myocardium was determined. The '4CO2 clearing the myocardium was plotted against time, and multiexponential curve fitting was performed with a VAX 780 computer.
Measurement of Myocardial Blood Flow
Myocardial blood flow was determined by injection of radiolabeled microspheres into the left atrium and by the arterial reference sampling technique.14 Approximately 2x 106 microspheres (diameter, 16.5±1 mm) labeled with '13Sn, 103Ru, 95Nb, 57Co, or 46Sc (NEN-TRAC microspheres, Du Pont, North Billerica, Massachusetts) were injected into the left atrium. Arterial blood was withdrawn with a Harvard infusion pump at a rate of 7.8 ml/min for 2 minutes. Blood and tissue sample activities were counted in a NaI (Tl) well counter after the end of the experiment. Regional myocardial blood flow in the myocardial segments supplied by the LAD was estimated from the area of anterior wall delineated by lissamine green staining.
Metabolic Measurements
Hemoglobin, hematocrit, blood gases, and serum levels of glucose, lactate, and free fatty acids were determined twice, once at the beginning and at the end of each experiment. Serum blood gases, glucose, lactate, and free fatty acid levels were measured as described previously.5 Myocardial oxygen, glucose, lactate, and free fatty acid consumptions were subsequently calculated from the measured arteriovenous differences, hematocrit levels and myocardial blood flow determined with microspheres and with the mean of the two determinations.
Statistical Analysis
Values are mean±SD. Comparison of results between experimental and control groups was performed by analysis of variance (ANOVA), followed by Dunnett's t test16 if an F test on the ANOVA indicated significant intergroup differences. Comparisons between two groups only were made by paired or unpaired t test as appropriate. Differences with a p value less than 0.05 were considered significant. Regression analysis was assumed to be sufficiently rigorous to make negligible the technical violation of independence due to performing two or three repeated experiments in the same animal.
Results
Hemodynamic and Metabolic Parameters
Hemodynamic parameters for the experimental groups are indicated in Table 1 . Dobutamine was found to be more effective than methoxamine and pacing, allowing stable increases in heart rate, systolic blood pressure, and rate-pressure product to be achieved. Although the pacing with methoxamine and morphine with propranolol groups did not produce significant hemodynamic changes by unpaired comparison with the nontreated group, intradog comparisons showed that pacing and methoxamine increased the rate-pressure product significantly compared with control conditions (p<0.03 by paired t test). Similarly, by paired t test, morphine and propranolol reduced the rate-pressure product significantly compared with control conditions (p<0.001). Myocardial blood flow was increased significantly by dobutamine and by dipyridamole and was decreased in ischemia compared with flow in studies without intervention. Regional myocardial blood flow in ischemic segments averaged 33.1 + 19.1% of flow in the surrounding nonischemic tissue (40.5-+±14.4 ml/100 g/min in the ischemic LAD territories and 135.7±40.9 ml/100 glmin in control myocardium). Systolic pressure tended to be lower in reperfusion experiments; the decrease in myocardial blood flow for all reperfusion experiments did not reach statistical significance.
Metabolic parameters are shown in Table 2 . The percentage of oxygen equivalents that could be accounted for by free fatty acid consumption was quite low, less than 40%, probably reflecting the arterial plasma concentration of fatty acids, which was also low. The exception to this were the dobutamine experiments, where the arterial plasma free fatty acid concentration, free fatty acid consumption, and percentage of oxygen equivalents consumed as free fatty acid were all increased compared with the experiments without intervention (baseline). Lactate consumption was decreased in ischemia and reperfusion, and net lactate production resulted in eight of the ischemic studies and one reperfusion study. The total percentage of oxygen equivalents consumed as free fatty acid and carbohydrate was not significantly different from 100% except for the percentage in the dipyridamole group, in which substrate uptake accounted for 190±109% of oxygen equivalents consumed because of a large significant increase in glucose uptake. An explanation for this effect might be increased glycogen storage during vasodilator treatment.
Myocardial 1C Tissue-Time Activity Curves After
Intracoronary []-"C]Acetate Injection (Figure 2 ). Conversely, starting an experiment with pacing and then ceasing electrical stimulation of the heart decreased the steepness of the slope markedly (results not shown). The rate constant kl for the rapid phase was found to be linearly related to MVo2 throughout a wide range of cardiac workload in 29 control experiments (Figure 4 ), in agreement with results obtained in vitro3 and in vivo throughout a less extensive range of oxygen consumption.5 Figure 4 also demonstrates that when the other experimental groups were included, a very similar relation between kl and oxygen consumption was observed overall. For ischemia and reperfusion experiments, significant linear relations were found between k1 and MVo2; correlation coefficients of 0.68 (p<0.02) and 0.76 (p<0.025) were obtained in ischemic and reperfused myocardium, respectively. For dipyridamole experiments, the relation between k1 and MVo2 was not significant (r=0.32); however, this probably reflects the very small range of MVo2 (309-479 ,umol/100 g/min) encompassed by this group. In addition to biexponential fitting, tissue-time activity curves were also fitted monoexponentially, with a short linear section of the rapid phase ( Figure  1A experiments. Figure 6 demonstrates that, although similar to control in hyperemia and reperfusion, the kl/MVo2 ratio was increased in the ischemia group (p<0.05). A similar increase in the kmonJMVO2 ratio in ischemia compared with the control group was also observed (p<0.05). When the ischemia experiments were compared to only those control experiments with MVo2 less than 450 ,umol/100 g/min, there was still a tendency for kl/MVo2 and kmonJMVO2 to be higher in the ischemia than in the control group; however, that trend was no longer significant. This may reflect the smaller number of experiments in the control group with MVo2 less than 10 ml/100 g/min (n=12). There was no significant trend to higher k/MVo2 ratios with lower MVo2 in the control group that might have explained this phenomenon. Because MVo2 was linearly related to blood flow, the linear relation between`1C clearance after acetate injection and MVo2 could theoretically also be influenced by effects of flow on clearance kinetics. To determine the effect of flow changes on k1 independent of changes in work load, the experiments in which flow and MVo2 were uncoupled with dipyridamole were compared with control experiments at similar MVo2. In the 13 dipyridamole experiments, kl/MVo2 was 0.021±0.003 compared with 0.019± 0.004 in the 10 control experiments, showing no significant difference despite a sixfold increase in flow with dipyridamole (482±+78 vs. 78±12 ml/100 g/min, p<0.001).
The dipyridamole experiments (group 2) demonstrated that kl was determined by MVo2 and not by myocardial blood flow; in experiments in which MVo2 was not uncoupled from myocardial blood flow (control group), kl was found to correlate (p<0.001) with myocardial blood flow (Figure 7) , reflecting the close relation between blood flow and MVo2 in normal myocardium. In contrast, with dipyridamole, the relation of kl to flow was abolished.
To determine the effects of myocardial substrate of`1C activity entering the rapid phase might be influenced by MVo2. For the control dogs, there was a significant relation between the relative size of the rapid phase and MVo2 (r=0.55, p<0.002). A significant relation was also found when all experimental groups were considered (r=0.46, p<0.001). Conversely, the relative amount of tracer entering the slower clearance phase was inversely correlated to MVo2 (p<0.003). The slope k2 of the second clear- ance phase ranged from 0.0004 to 0.02/min and was not found to be related significantly to MVo2 or metabolic parameters. Of note, accurate determination of k2 is hindered by low residual myocardial activity after 10-20 minutes and by interference of radioactivity from previous microsphere injections with the low count rate. Rate constants obtained exclusively for the initial hump phase (kini) also correlated well with MVo2 in 29 control experiments (r=0.90, Figure 8A ). Furthermore, there was a close correlation between kini, and the maximum of myocardial CO2 production after injection of [1-14C]acetate ( Figure 8B, r=0 and 15 minutes after injection is summarized in Figure 9 . This period was chosen because the major fitting parameters are determined within this time frame. After injection of [1-11C]acetate, '4CO2 accounted for 97.4+2.5% of total myocardial J4C efflux in the control group, 89.1±2.6% in ischemia (p<0.002 vs. control group), 94.1+3.5% after reperfusion (p=NS vs. control group) and more than 99% with dipyridamole (p=NS vs. control group). Of note, at high myocardial blood flows (with dipyridamole and dobutamine), the arteriovenous difference for non-CO2 14C activity was very small, precluding accurate measurement. In the first measurements 1-2 minutes after injection of [1-14C]acetate (mean, 1.8+1.0 minutes), the amount of non-CO2 14C activity was considerably higher (4.8±+ 6.4% in control, 50+12% in ischemia, and 26+23% in reperfusion groups; negligible in the dipyridamole and dobutamine groups). When biexponential fitting was Figure 10 ). Visual begins was consistently seen in all experiments and tion of the linear fit suggested a possible small was termed the hump phase. The effect may be due on from linearity at low kl; reanalysis of the to two different mechanisms. First, equilibration of ith a binomial fit also gave a good correlation label into TCA cycle intermediates mav require 8) with a decreased residual sum of squares several minutes, depending on the speed of TCA Is. 0.023), but the improvement in fit did not cycle turnover. Randle et al19 and Chance et a120 statistical significance (F test). When the con-demonstrated in rat hearts that labeling of the small periments were considered alone, a linear fit acetyl-CoA pool requires only about 10 seconds, 9) was obtained.
whereas the labeling of all the TCA cycle intermediates required several minutes in most instances.1920
Discussion
This hypothesis would be consistent with our findings study confirms the usefulness of [ The possible slight trend toward nonlinearity at low values of kl may reflect the small increase in non-CO2 activity in ischemia.
Further evidence that recirculation does not play a major role in [1-"C]acetate kinetics is the fact that slopes for the relation between kl and MVo2 were nearly identical after intracoronary injection in this study (y=0.005+0.00041x) and after intravenous tracer injection in two recent studies with "C acetate and PET (Buxton et a15: y=0.0393+0.00035x; Brown et a16: y=0.02+0.00039x). Thus, [1-1"C]acetate washout represented myocardial CO2 production and thus TCA cycle turnover in the same way after intracoronary and intravenous injections.
Clearance kinetics after intracoronary [1-"'Cacetate injection are also largely insensitive to changes in myocardial substrate supply and selection. Because the proportion of oxygen consumed by the TCA cycle oxidations is similar for all major substrates (2/3 for glucose and lactate, 16/23 for palmitate, and 18/25 for oleate), this result is not unexpected. In the control dogs, an increase in the percentage of oxygen equivalents accounted for by fatty acid uptake was accompanied by a small decrease in the k/MVo2 ratio. Similar results were obtained in closed-chest dogs with noninvasive measurement of acetate tissue kinetics by PET.5 Several studies have demonstrated increased oxygen consumption with increasing free fatty acid utilization despite constant hemodynamic parameters,22-24 although others have been unable to reproduce this "oxygen wasting" effect.25 A decrease in myocardial efficiency when utilizing free fatty acid leading to a higher MVo2 for a given cardiac workload and TCA cycle turnover would account for the changes in the k/MVo2 ratio observed in this study. The quantitative impact of free fatty acid metabolism on the kl/MVo2 ratio is small; however, a shift in fatty acid consumption from 25% to 75% of MVo2 would lead to a decrease in the k/MVo2 ratio of about 12%. Because high arterial lactate levels inhibit myocardial free fatty acid oxidation,26 the effects of high arterial lactate in increasing the kl/MVo2 ratio might be attributable to this mechanism. However, arterial lactate levels did not correlate significantly with free fatty acid consumption, expressed as a percentage of myocardial oxygen consumption in this study (r=0.21, NS), and hence, the mechanism of action of lactate is unclear. An increase in arterial lactate concentration from low (0.5 mM) to high (1.4 mM) resting physiological plasma levels would increase the kl/MVo2 ratio by about 20%. The effect that high concentrations of lactate resulting from exercise would have on acetate kinetics is unknown. However, in another study27 testing ["Clacetate with PET in human myocardium, no such dependence of ["C] acetate washout on substrate levels was found.
The relation between kl (and kmono) and MVo2 was unaltered by dipyridamole-induced hyperemia and in myocardium reperfused after a 30-minute occlusion of the LAD. However, in ischemic myocardium, an increase of approximately 15-20% was observed in the kJMVo2 ratio. One possible mechanism contributing to this increase would be the small increase in non-CO2 tracer material observed in ischemia, which may wash out more rapidly than the labeled CO2. Another contributory factor might be increased carbohydrate utilization in ischemic myocardium, which has been shown to increase the kl/MVo2 ratio.5 Mean carbohydrate utilization (as a percentage of oxygen equivalents) was greater in the ischemia than in the control group (72±15% vs. 51±28%), although the difference was not significant. It should also be noted that determination of MVo2 in the ischemic zone would be expected to be less accurate than for the other groups, because inhomogeneity of flow and oxygen consumption are likely to occur and because difficulties in determination of the LAD perfusion bed may also introduce errors. Increased collateral flow is also likely in ischemia,27,28 which would lead to an underestimation of MVo2 and hence an overestimation of the kl/MVo2 ratio. Such errors may also contribute to the larger standard deviation of the kl/MVo2 ratio for the ischemic group. Thus, systematic errors in determination of MVo2 could contribute to the apparent change in the k1/MVo2 ratio.
Accurate biexponential fitting of [1-11C]acetate tissue-time activity curves requires relatively long acquisition times. Because the rate-pressure product is generally lower in humans than in anesthetized dogs, this situation will be exacerbated, particularly in ischemic segments where MVo2 is reduced. With the short (20-minute) physical half-life of 'C, obtaining adequate counting statistics at later times may become limiting. In addition, long acquisition times are undesirable, particularly in critically ill patients. Because changes in myocardial work load affect the acetate clearance kinetics, MVo2 must also be maintained constant throughout the study. The demonstration that km,,,, which was obtained by monoexponential fitting of the initial linear portion of the clearance curve, traces myocardial oxidative metabolism as well as kl suggests that short acquisitions with monoexponential fitting of tissue-time activity curves will be of value in patient studies.
Results obtained in vitro and in vivo support the hypothesis that the rapid phase of acetate clearance represents direct oxidation of labeled acetate by the TCA cycle. The fraction of the injected amount of [1-1"C]acetate entering the rapid clearance phase increased with rising MVo2, demonstrating that increased workload leads to a greater fraction of acetate undergoing direct oxidation. The slower phase has not been characterized but is likely to represent entry of label into amino acid pools in equilibrium with TCA cycle intermediates. The major alternative to direct oxidation of acetate has been shown to be conversion to glutamate (by transamination of 2-oxoglutarate) and to aspartate (by transamination of oxaloacetate). 19 The results are thus consistent with elevated TCA cycle flux that causes increased competition for tracer between the TCA cycle reactions and transamination reactions, resulting in less activity entering the amino acid pools.
One limitation of the present study is the use of anesthetized dogs and consequent changes in metabolic and hormonal regulatory mechanisms. Although substrate utilization and catecholamine stimulation appear to have minimal effects on the relation between acetate kinetics and MVo2, studies in conscious animals would be of merit to confirm that results are similar.
In conclusion, this study extends previous findings in vitro and in vivo by supporting the validity of [1-'1C]acetate for the noninvasive measurement of regional myocardial oxygen consumption in vivo with PET. The relation between rate constants for the early rapid phase of tracer clearance after [1-"C]acetate administration and MVo2 was unchanged in hyperemic and postischemic myocardium, whereas only a small increase in the kl/MVo2 ratio was observed in ischemia.
Myocardial fuel supply and selection have only minimal effects on [1-1'C]acetate kinetics. Quantitative measurement of regional MVo2 with [1-11C]acetate and PET may be of value for assessing residual oxidative metabolism in jeopardized myocardium, which can assist in clinical decision making in patients with coronary artery disease.
